These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33135887)

  • 1. Synthetic Lethality through the Lens of Medicinal Chemistry.
    Myers SH; Ortega JA; Cavalli A
    J Med Chem; 2020 Dec; 63(23):14151-14183. PubMed ID: 33135887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.
    Kantidze OL; Velichko AK; Luzhin AV; Petrova NV; Razin SV
    Trends Cancer; 2018 Nov; 4(11):755-768. PubMed ID: 30352678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
    Ngoi NYL; Pham MM; Tan DSP; Yap TA
    Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
    Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
    Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 8. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
    Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
    J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
    Ariumi Y; Turelli P; Masutani M; Trono D
    J Virol; 2005 Mar; 79(5):2973-8. PubMed ID: 15709017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR.
    Dhoonmoon A; Schleicher EM; Clements KE; Nicolae CM; Moldovan GL
    Nucleic Acids Res; 2020 Jul; 48(13):7252-7264. PubMed ID: 32542389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
    Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
    Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
    Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
    Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.
    Tang Q; Wang X; Wang H; Zhong L; Zou D
    Cancer Biol Med; 2024 Feb; 20(12):915-21. PubMed ID: 38318945
    [No Abstract]   [Full Text] [Related]  

  • 17. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An
    Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
    Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 53BP1 mediates the fusion of mammalian telomeres rendered dysfunctional by DNA-PKcs loss or inhibition.
    Rybanska-Spaeder I; Ghosh R; Franco S
    PLoS One; 2014; 9(9):e108731. PubMed ID: 25264618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.